An JH, Moon SJ, Shin JU, et al. - The efficacy of systemic clindamycin (CL) mono-therapy was investigated in patients with hidradenitis suppurativa (HS) patients. In addition, the prevalence and CL resistance of bacterial growth were assessed.

• Among a total of 53 HS patients treated with CL mono-therapy, 34 were eligible for evaluation of the efficacy of the therapy.

• Outcomes suggest that for HS patients, systemic CL mono-therapy may be a safe and valuable alternative to rifampicin (RF)-CL combination therapy.

• CL resistance was prevalent in 15.00%.

• The efficacy of the CL mono-therapy did not differ significantly depending on the presence of CL-resistant bacteria.